Binds Parasitic Protozoan Or Metazoan Cell Or Component Or Product Thereof (e.g., Dirofilaria, Eimeria, Coccidia, Trichinella, Parasite Cell-surface Antigen, Etc.) Patents (Class 530/388.6)
  • Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications
    Patent number: 6392014
    Abstract: The invention relates to cloning of the gene for the toxoplasma GP28.5 antigen. It also encompasses purified GP28.5 antigen preparations and antigenic polypeptides derived from said antigen, and their applications.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: May 21, 2002
    Inventors: Marie-France Cesbron, Corinne Mercier, André Capron, André Tartar, Pierrette Maes
  • Method to detect Dirofilaria immitis infection
    Patent number: 6391569
    Abstract: The present invention includes a method to detect D. immitis infection in a host animal using a D. immitis Di33 protein to detect anti-D. immitis Di33 antibodies in a bodily fluid of the animal. Also included is a method to detect D. immitis infection in a host animal using a D. immitis anti-Di33 protein to detect Di33 proteins in a bodily fluid of the animal. The present invention also relates to D. immitis detection kits that include either a Di33 protein or an anti-Di33 antibody; such kits also include a composition to detect an immunocomplex between the anti-Di33 antibody and D. immitis Di33 protein. The present invention also includes Di33 proteins, nucleic acid molecules encoding such proteins, as well as recombinant molecules and recombinant cells comprising such nucleic acid molecules, and anti-Di33 antibodies. Also included are methods to produce such proteins, nucleic acid molecules and antibodies.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: May 21, 2002
    Assignee: Heska Corporation
    Inventors: Robert B. Grieve, Glenn R. Frank, Roy R. Mondesire, James P. Porter, Nancy Wisnewski
  • Antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
    Patent number: 6344337
    Abstract: The present invention provides an immunoassay to detect identifying antigens in horses that are infected with Sarcocystis neurona. The immunoassay is preferably an antigen-capture-based assay that relies upon polyclonal or monoclonal antibodies against a 16 (±4) and/or 30 (±4) kDa antigens specific to Sarcocystis neurona to detect the presence of the 16 (±4) and/or 30 (±4) kDa antigens in equine serum or equine cerebrospinal fluid.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: February 5, 2002
    Assignee: Board of Trustees of Michigan State University
    Inventors: Linda S. Mansfield, Mary G. Rossano, Alice J. Murphy, Ruth A. Vrable
  • Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
    Patent number: 6303755
    Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: October 16, 2001
    Assignee: Medarex, Inc.
    Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
  • Methods to block IGE binding to cell surface receptors of mast cells
    Patent number: 6299875
    Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: October 9, 2001
    Assignee: Panacea Pharmaceuticals, LLC
    Inventors: Michael Caplan, Howard Sosin
  • Trypanosoma cruzi antigen, gene encoding therefor and methods of detecting and treating chagas disease
    Patent number: 6270767
    Abstract: The nucleotide sequence of Tc100, a gene encoding PTc100, a new Trypanosoma antigen, and the amino acid sequence of PTc100 are described. Tc100 and PTc100, or fragments thereof, modified or otherwise, can be used directly or indirectly for the detection of Trypanosoma cruzi, or for the monitoring of the infection generated by Trypanosoma cruzi, in man or in animals.
    Type: Grant
    Filed: August 24, 1998
    Date of Patent: August 7, 2001
    Assignee: Bio Merieux
    Inventors: Glaucia Paranhos-Baccala, Mylene Lesenechal, Michel Jolivet
  • Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
    Patent number: 6248326
    Abstract: The present invention provides an inhibitor of osteoblastic stem cell factor binding and/or activity, for example, an antibody or an antisense oligonucleotide. Also provided are pharmaceutical compositions comprising these inhibitors of osteoblastic stem cell factor binding and/or activity. Further provided is a method of regulating the activity of osteoclasts, comprising the step of: inhibiting the binding and/or activity of osteoblastic stem cell factor.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: June 19, 2001
    Inventors: Harry C. Blair, Sai-Sai Dong, Bruce A. Julian